Skip to main content
SpringerLink
Log in

Bempedoinsäure – ein neuer Spieler in der Lipidtherapie

Bempedoic acid—a new player in lipid therapy

  • Journal Club
  • Published:
Der Kardiologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Pinkosky S, Newton R, Day E et al (2016) Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun 7:13457. https://doi.org/10.1038/ncomms13457

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM (2019) CLEAR harmony trial. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 380(11):1022–1032

    Article  CAS  Google Scholar 

  3. Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB (2019) Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA 322(18):1780–1788

    Article  CAS  Google Scholar 

  4. Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, Kelly S, Stroes ESG (2019) Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc 8(7):e11662

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardioangiologisches Centrum Bethanien (CCB), Frankfurt, Deutschland

    Holger Eggebrecht

Authors
  1. Holger Eggebrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Holger Eggebrecht.

Ethics declarations

Interessenkonflikt

H. Eggebrecht gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eggebrecht, H. Bempedoinsäure – ein neuer Spieler in der Lipidtherapie. Kardiologe 15, 170–171 (2021). https://doi.org/10.1007/s12181-021-00447-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12181-021-00447-y

Search

Navigation